This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
In a rising broad market and a mixed commodity price backdrop, midstream stocks traded up but lagged the S&P 500 and utilities this week. Recent midstream corporation and utility outperformance has helped the Alerian Energy Infrastructure Index (AMEI) cut into the YTD lead the Alerian MLP Index has maintained since the MLP spike in January.
BKEP TGE PAGP SMLP ENB KEY IPL TEP BPL TEGP CEQP NSH OKE.WI EBBNF OKE BIP MMP IPPLF ENBBF BWP NS.PRC ENB NS.PRB PPL SEMG NS NS.PRA
Enbridge Energy Partners, L.P. (EEP - Free Report) was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.79 to $10.40 in the past one-month time frame.
75 U.S. stocks displayed 9%+ forward yield, $5+ prices, $100M+ market caps, and .25%+1Yr. targets 6/20/18. Yields above 10.96% narrowed Summer WallStars to 30 for show.
CCR GARS CLA MMLP SMLP DLNG ORC BPL CCLP USAC DLNG.PRA GMLP CAPL CPTA EEP SNMP
The historic summit between President Donald Trump and North Korea leader Kim Jong Un in Singapore has created history, possibly ending bitterness that lasted for 68 years. This is especially true as Trump and Kim signed an agreement, which offers undisclosed American “security guarantees” in exchange for a commitment from North Korea to “work toward complete denuclearization of the Korean Peninsula.
ABX NEM LULU TRI FITB SMLP FITBI ABX
Currently, Summit Midstream Partners (SMLP) is trading at a yield close to 15%. The company announced a distribution of $0.58 per unit for the first quarter, which remained unchanged sequentially. On May 8, RBC cut its target price for Summit Midstream from $20 to $18. Of the analysts surveyed by Reuters, 30% of the analysts rated Summit Midstream Partners stock as a “buy,” 60% rated it as a “hold,” and 10% rated it as a “sell.
NGL NGL.PRB MMLP SMLP
Energy firms with at least 0.71 broker target upside and 2% dividend yield showed midstream firms high on lists led by Blueknight Energy for upside and Sandridge for yield.
NGL ETP.PRC NGL.PRB MMLP SMLP BPL SRLP CCLP GNE ETP CAPL GPP GNE EEP GEL SNMP
77 U.S. stocks displayed 10%+ forward yield, $2+ prices, and $100M+ market caps and positive broker targets as of 5/11/18. Yields above 12.0% narrowed the list to 30 for comparison.
BKEP NGL ETP.PRC DDR GARS NGL.PRB AIC MMLP SMLP DLNG ORC DDR.PRJ ETP DLNG.PRA AI OFS DDR.PRK AI.PRB MDLY DDR.PRA EEP AIW
Energy Transfer Equity, L.P. (ETE - Free Report) reported first-quarter 2018 earnings of 42 cents per unit, lagging the Zacks Consensus Estimate of 46 cents by 8.7%. However, the bottom line improved by 82.6% compared with the year-ago figure of 23 cents. Total Revenues In the quarter under review, Energy Transfer Equity’s total revenues came in at $11,882 million, surpassing the Zacks Consensus Estimate of $11,053 million by 7.
ENBL SMLP EPD
Summit Midstream Partners (SMLP) is a curious contender for investors in the MLP space. On one hand, the company's yield is attractive for high-yield income investors. On the other, that yield has been driven up for a reason: the market is concerned about SMLP's ability to sustain its distribution and is pricing in a potential reduction to its payout. So investors must evaluate that risk ahead of any other consideration.
Welcome to the Q1 2018 Summit Midstream Partners, LP Earnings Conference Call. My name is John, and I'll be your operator for today's call. [Operator Instructions]. All participants are on a listen only mode. [Operator Instructions] Please note that this conference is being recorded.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET